Work

Alzheimer's disease and blood-based biomarkers – potential contexts of use

Year: 2018
Type: review
Abstract: Alzheimer's disease (AD) is an irreversible, incurable, progressive neurodegenerative illness, where dementia symptoms gradually worsen over a number of years. The research of validated biomarkers for AD is essential to improve diagnosis and accelerate the development of new therapies. Biochemical markers including neuroimaging could facilitate diagnosis, predict AD progression from a pre-AD state of mild cognitive impairment, and be used to detect the efficacies of disease-modifying therapies. Established biomarkers of AD from cerebrospinal fluid and neuroimaging are highly accurate, but barriers to clinical implementation exist. The focus on blood-based AD biomarkers has grown exponentially during the past few decades. An ideal diagnostic test for AD should be noninvasive and easily applicable. Clinical cost-effectiveness also needs to be established.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,836
OpenAlex ID: W2882991329
FWCI: 0.687
Cites: 36
Cited by: 62
Related to: 10